A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase-Reference-Cited by-同舟云学术

A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Published:2013-12 Issue:6 Volume:13 Page:646-656
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Jabbour Elias,Lipton Jeffrey H.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference62 articles.

1. Molecular biology of bcr-abl1–positive chronic myeloid leukemia;Quintás-Cardama;Blood,2009

2. Chronic myeloid leukemia: diagnosis and treatment;Quintás-Cardama;Mayo Clin Proc,2006

3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia Version 4.2013. Fort Washington, PA: National Comprehensive Cancer Network; 2013. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 1, 2013.

4. Gleevec® (imatinib mesylate) [prescribing information],2013

5. Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review;Frontiers in Pharmacology;2024-02-01

3. Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia;Medical Oncology;2022-06-18

4. Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study;Supportive Care in Cancer;2022-03-18

5. Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis;Journal of Medicinal Chemistry;2021-10-08